New combo attack on kidney cancer: radiation plus two drugs
NCT ID NCT07470840
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial will test a combination of precise radiation (SBRT) and two drugs—anlotinib (which cuts off tumor blood supply) and bemarituzumab (which boosts the immune system)—in 27 people with advanced kidney cancer that cannot be surgically removed. The main goal is to see how many patients' tumors shrink significantly. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anlotinib (oral anti-angiogenic drug) and bemarituzumab (intravenous immunotherapy), plus stereotactic body radiation therapy (SBRT)
- What this could lead to
- If successful, this combination could offer a new treatment option that shrinks tumors and delays progression in advanced kidney cancer.
- What could go wrong
- This is a small, early-phase trial (27 people) with no results yet. The combination may cause significant side effects, and the benefit may not be confirmed in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.